Skip to main navigation
Header Menu
Logo
  • About
    • Overview
    • Management
    • Board of Directors
  • Products
    • SYMJEPI® (epinephrine)
    • ZIMHI™ (naloxone)
  • Pipeline
  • Patients
  • Investors & Media
    • Overview
    • News Releases
    • Stock Information
    • SEC Filings
    • Events & Presentations
    • Email Alerts
    • Governance
  • Partnerships
  • Contact Us

News Releases

Date Title View
May 25, 2023 Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
PDF Version
May 19, 2023 Adamis Pharmaceuticals Announces Reverse Stock Split
PDF Version
May 15, 2023 Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
PDF Version
May 08, 2023 Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
PDF Version
Mar 16, 2023 Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
PDF Version
Mar 14, 2023 Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
PDF Version
Mar 14, 2023 Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
PDF Version
Feb 27, 2023 Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger
PDF Version
Feb 22, 2023 Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements
PDF Version

Sign Up For Adamis Pharmaceuticals Email Alerts

Choose Your Preferences
Adamis

Adamis Pharmaceuticals is a clinical stage neuro-biotechnology company focused on the development and commercialization of potential blockbuster products for the treatment of a variety of neuro-based disorders with significant unmet medical needs.

02. Footer - Social Links
  • LinkedIn
  • Twitter
Footer - Column 2
COMPANY
  • About Us
  • Overview
  • Management
  • Board of Directors
Products
  • SYMJEPI® (epinephrine)
  • ZIMHI® (naloxone)
Pipeline
  • Specialty Pharmaceuticals
  • APC-400 (tempol) – Capsule
Footer - Column 3 (Hidden on Desktop)
Investors & Media
  • Overview
  • News Releases
  • Stock Information
  • SEC Filings
  • Events & Presentations
  • Email Alerts
  • Corporate Governance
Connect
  • Careers
  • Partnerships
  • Contact Us
Footer - Column 4
Products
  • SYMJEPI® (epinephrine)
  • ZIMHI® (naloxone)
Pipeline
  • New Molecular Entities
Footer - Column 5
Investors & Media
  • Overview
  • News Releases
  • Stock Information
  • SEC Filings
  • Events & Presentations
  • Corporate Governance
  • Email Alerts
Footer - Column 6
Connect
  • Careers
  • Partnerships
  • Contact Us

© 2023 Copyright Adamis Pharmaceuticals Corp

Footer Copyright Links
  • Terms and Conditions
  • Privacy Policy